Dr. Hugh James Freeman, MD, FRCPC, FACP, Department of Medicine (Gastroenterology), University of British Columbia Hospital, 2211 Wesbrook Mall, Vancouver V6T 1W5, Canada. email@example.com
Article-Type of This Article
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastroenterol. May 7, 2009; 15(17): 2078-2080 Published online May 7, 2009. doi: 10.3748/wjg.15.2078
Tropheryma whipplei Infection
Hugh James Freeman
Hugh James Freeman, Department of Medicine (Gastroen-terology), University of British Columbia, Vancouver V6T 1W5, Canada
ORCID number: $[AuthorORCIDs]
Author contributions: Freeman HJ contributed the entire paper.
Correspondence to: Dr. Hugh James Freeman, MD, FRCPC, FACP, Department of Medicine (Gastroenterology), University of British Columbia Hospital, 2211 Wesbrook Mall, Vancouver V6T 1W5, Canada. firstname.lastname@example.org
Received: March 11, 2009 Revised: April 7, 2009 Accepted: April 14, 2009 Published online: May 7, 2009
Whipple’s disease was initially described in 1907. Over the next century, the clinical and pathological features of this disorder have been better appreciated. Most often, weight loss, diarrhea, abdominal and joint pain occur. Occasionally, other sites of involvement have been documented, including isolated neurological disease, changes in the eyes and culture-negative endocarditis. In the past decade, the responsible organism Tropheryma whipplei has been cultivated, its genome sequenced and its antibiotic susceptibility defined. Although rare, it is a systemic infection that may mimic a wide spectrum of clinical disorders and may have a fatal outcome. If recognized, prolonged antibiotic therapy may be a very successful form of treatment.
Whipple’s disease was first described in 1907. It required almost 100 years before the responsible organism, Tropheryma whipplei (T. whipplei) was cultivated, its genome sequenced and its antibiotic susceptibility defined[1–5]. Detailed and authoritative reviews regarding the disease have also recently appeared. Whipple’s disease is known to mimic a wide spectrum of medical conditions, and yet, only 1500 cases or so have been described to date in the literature. Most expert clinicians, including specialist gastroenterologists, never see a single case over the course of their entire careers, however this disease is a principal bacterial cause of chronic malabsorption. As such, recognition of Whipple’s disease should not be minimized since timely treatment might impact on the outcome of this potentially fatal disorder.
ORGANISM AND HOST FACTORS
Whipple’s disease often affects middle-aged Caucasian men (but not exclusively), causing weight loss, arthralgia, diarrhea, steatorrhea and abdominal pain. Occasionally, other atypical presentations may occur due to involvement of the heart, lungs or central nervous system. The responsible organism is rod-shaped and can be seen in many different ultrastructural forms present in cells and extracellular spaces. Usually, the organism is detected within macrophages of the lamina propria of the small intestine and its lymphatic drainage. The organisms, however, may also occur in epithelial cells as well as cells of the immune system. Because of genetic heterogeneity, some strains are non-pathogenic or may cause atypical clinical presentations such as an isolated infectious form of endocarditis. Using a polymerase chain reaction (PCR) method, researchers found T. whipplei occurring in the environment and it has been documented in sewage water, fecal material and in sewage plant workers without Whipple’s disease. There may be a selective immune defect in host T-cells (or macrophages) that leads to Whipple’s disease, or alternatively, these immune defects may be secondary and caused by T. whipplei itself.
CLINICAL AND LABORATORY FEATURES
Table 1 displays common clinical and laboratory features of T. whipplei infection. In some cases, there is a “prodromal phase” with fever and isolated joint manifestations, including arthralgia, preceding any gastrointestinal symptoms. These joint symptoms may be migratory in type and rheumatoid-factor-negative. Large joints may be involved more often than small joints alone and there may be treatment resistance to antirheumatic drugs. Duodenal biopsies may be negative, but synovial fluid and biopsies examined using PCR, immunohistochemistry or electron microscopy may reveal the diagnosis. Diarrhea, weight loss and malabsorption associated with low serum carotene may occur. Anemia with an elevated sedimentation rate may develop. Peripheral edema with hypoalbuminemia and ascites (associated with protein-losing enteropathy) may develop later in the clinical course. Endoscopic changes may be noted in some, but not all, patients and have recently been illustrated by Armelao et al. Essentially, duodenal folds appear thickened and erythematous and yellow-white plaques may be seen. Duodenal biopsies are still the basis for diagnosis in the majority of cases and have been illustrated well elsewhere. The histological features can be readily appreciated on standard hemotoxylin-eosin-stained sections of mucosal biopsies as massive infiltration of the lamina propria with foamy macrophages. These macrophages contain the organism. A periodic acid-Schiff (PAS) stain will confirm the suspected diagnosis. Rarely, the infiltrate may be limited to the submucosa. Lamina propria plasma cells and lymphocytes are not increased; indeed, with extensive macrophage infiltration, they may appear to be decreased. Small collections of fat may also be present in the lamina propria (thus, the term intestinal lipodystrophy coined by Whipple) and the overlying villus epithelium may appear vacuolated because of fat accumulation. In part, this may reflect obstruction of lamina propria lacteals and regional lymphatics by lymph node involvement. After treatment, the bacilli may disappear and the macrophage numbers become reduced, but both may persist for years.
Table 1 Clinical and laboratory changes in T. whipplei infection.
Clinical and laboratory changes
Low serum carotene
Low serum albumin
Elevated sedimentation rate
Approximately a quarter of patients with Whipple’s disease develop neurological changes, and some, despite treatment, are irreversible. Neurological change may be the initial clinical feature, and rarely may occur in isolation[19–21]. Cognitive manifestations, such as dementia, are common. Altered ocular movements may occur, including a progressive form of supranuclear ophthalmoplegia. Headache, psychiatric changes, focal or generalized seizures and ataxia are frequent. Even without neurological symptoms, cerebrospinal fluid infection may be defined by PCR analysis. Ocular involvement may include uveitis, retinitis and optic neuritis with papilloedema. Historically, the disorder has been recognized as a form of culture-negative endocarditis. Diagnosis by valve explantation has been recorded.
Laboratory diagnosis of T. whipplei infection is still largely based on duodenal biopsy. Foamy macrophages in the lamina propria are seen that are PAS-positive, but diastase-resistant. Possibly, this positive staining reaction is related to the inner membrane of the polysaccharide bacterial cell wall. A Ziehl-Nielsen stain (most typically used for mycobacteria species) is negative. Other sites, e.g. lymph nodes, may also yield a classic PAS-positive staining reaction in the macrophages. PCR has a high sensitivity and specificity but is not recommended for screening because healthy carriers with a positive PCR have been noted. Recent studies using quantitative PCR on saliva and fecal materials make a case for a role of PCR in initial evaluation, followed by more invasive biopsy evaluation. Immunostaining with specific T. whipplei antibodies may reveal the organism in PAS-negative tissues. Other biomarker methods are being explored.
Before antibiotic treatment, a fatal course was often recorded. Later, tetracycline was often used, but recurrence was common and more recent treatment recommendations have been based on antibiotics that are capable of crossing the blood-brain barrier. Recent recommendations suggest that a 2-wk course of intravenous ceftriazone to achieve high cerebrospinal fluid levels, followed by twice daily cotrimoxazole for 1 year is very effective. Most recover completely, although central nervous system symptoms may not resolve. Others have suggested trimethoprim-sulfamethoxazole twice daily for
1-2 years. Interestingly, treatment may be successful even if the diagnosis is established many decades after the onset of symptoms.
If ceftriaxone hypersensitivity is evident, then induction has been recommended with penicillin, cephalosporins, carbapenems, or chloramphenicol. As an alternative to long-term cotrimoxazole, combination doxycycline and hydroxychloroquine have been recommended.
Recurrent neurological changes in Whipple’s disease have a poor prognosis, and use of interferon gamma therapy has been described.
Peer reviewer: Dr. Gert De Hertogh, Morphology and Molecular Pathology, University Hospitals KULeuven, 3000 Leuven, Belgium
Raoult D, Birg ML, La Scola B, Fournier PE, Enea M, Lepidi H, Roux V, Piette JC, Vandenesch F, Vital-Durand D. Cultivation of the bacillus of Whipple's disease.N Engl J Med. 2000;342:620-625.
Bentley SD, Maiwald M, Murphy LD, Pallen MJ, Yeats CA, Dover LG, Norbertczak HT, Besra GS, Quail MA, Harris DE. Sequencing and analysis of the genome of the Whipple's disease bacterium Tropheryma whipplei.Lancet. 2003;361:637-644.
Raoult D, Ogata H, Audic S, Robert C, Suhre K, Drancourt M, Claverie JM. Tropheryma whipplei Twist: a human pathogenic Actinobacteria with a reduced genome.Genome Res. 2003;13:1800-1809.
Boulos A, Rolain JM, Raoult D. Antibiotic susceptibility of Tropheryma whipplei in MRC5 cells.Antimicrob Agents Chemother. 2004;48:747-752.
Boulos A, Rolain JM, Mallet MN, Raoult D. Molecular evaluation of antibiotic susceptibility of Tropheryma whipplei in axenic medium.J Antimicrob Chemother. 2005;55:178-181.
Yardley JH, Hendrix TR. Combined electron and light microscopy in Whipple's disease. Demonstration of "bacillary bodies" in the intestine.Bull Johns Hopkins Hosp. 1961;109:80-98.
Lepidi H, Fenollar F, Dumler JS, Gauduchon V, Chalabreysse L, Bammert A, Bonzi MF, Thivolet-Béjui F, Vandenesch F, Raoult D. Cardiac valves in patients with Whipple endocarditis: microbiological, molecular, quantitative histologic, and immunohistochemical studies of 5 patients.J Infect Dis. 2004;190:935-945.
Maiwald M, Schuhmacher F, Ditton HJ, von Herbay A. Environmental occurrence of the Whipple's disease bacterium (Tropheryma whippelii).Appl Environ Microbiol. 1998;64:760-762.
Schöniger-Hekele M, Petermann D, Weber B, Müller C. Tropheryma whipplei in the environment: survey of sewage plant influxes and sewage plant workers.Appl Environ Microbiol. 2007;73:2033-2035.
Moos V, Kunkel D, Marth T, Feurle GE, LaScola B, Ignatius R, Zeitz M, Schneider T. Reduced peripheral and mucosal Tropheryma whipplei-specific Th1 response in patients with Whipple's disease.J Immunol. 2006;177:2015-2022.
Fleming JL, Wiesner RH, Shorter RG. Whipple's disease: clinical, biochemical, and histopathologic features and assessment of treatment in 29 patients.Mayo Clin Proc. 1988;63:539-551.
Maizel H, Ruffin JM, Dobbins WO 3rd. Whipple's disease: a review of 19 patients from one hospital and a review of the literature since 1950. 1970.Medicine (Baltimore). 1993;72:343-355.
Armelao F, Portolan F, Togni R. Mosaic-patterned and scalloped duodenal mucosa in Whipple's disease.Clin Gastroenterol Hepatol. 2008;6:A32.
Lewin KJ, Riddell RH, Weinstein WM. Gastrointestinal pathology and its clinical implications. Igaku-Shoin: New York; 1992;779-782.
Keinath RD, Merrell DE, Vlietstra R, Dobbins WO 3rd. Antibiotic treatment and relapse in Whipple's disease. Long-term follow-up of 88 patients.Gastroenterology. 1985;88:1867-1873.
Gerard A, Sarrot-Reynauld F, Liozon E, Cathebras P, Besson G, Robin C, Vighetto A, Mosnier JF, Durieu I, Vital Durand D. Neurologic presentation of Whipple disease: report of 12 cases and review of the literature.Medicine (Baltimore). 2002;81:443-457.
Mendel E, Khoo LT, Go JL, Hinton D, Zee CS, Apuzzo ML. Intracerebral Whipple's disease diagnosed by stereotactic biopsy: a case report and review of the literature.Neurosurgery. 1999;44:203-209.
Panegyres PK, Edis R, Beaman M, Fallon M. Primary Whipple's disease of the brain: characterization of the clinical syndrome and molecular diagnosis.QJM. 2006;99:609-623.
von Herbay A, Ditton HJ, Schuhmacher F, Maiwald M. Whipple's disease: staging and monitoring by cytology and polymerase chain reaction analysis of cerebrospinal fluid.Gastroenterology. 1997;113:434-441.
Avila MP, Jalkh AE, Feldman E, Trempe CL, Schepens CL. Manifestations of Whipple's disease in the posterior segment of the eye.Arch Ophthalmol. 1984;102:384-390.
Houpikian P, Raoult D. Blood culture-negative endocarditis in a reference center: etiologic diagnosis of 348 cases.Medicine (Baltimore). 2005;84:162-173.
Fenollar F, Laouira S, Lepidi H, Rolain JM, Raoult D. Value of Tropheryma whipplei quantitative polymerase chain reaction assay for the diagnosis of Whipple disease: usefulness of saliva and stool specimens for first-line screening.Clin Infect Dis. 2008;47:659-667.
Baisden BL, Lepidi H, Raoult D, Argani P, Yardley JH, Dumler JS. Diagnosis of Wihipple disease by immunohistochemical analysis: a sensitive and specific method for the detection of Tropheryma whipplei (the Whipple bacillus) in paraffin-embedded tissue.Am J Clin Pathol. 2002;118:742-748.
Kowalczewska M, Raoult D. Advances in Tropheryma whipplei research: the rush to find biomarkers for Whipple's disease.Future Microbiol. 2007;2:631-642.
Caples SM, Petrovic LM, Ryu JH. Successful treatment of Whipple disease diagnosed 36 years after symptom onset.Mayo Clin Proc. 2001;76:1063-1066.
Schneider T, Stallmach A, von Herbay A, Marth T, Strober W, Zeitz M. Treatment of refractory Whipple disease with interferon-gamma.Ann Intern Med. 1998;129:875-877.